Femtech firm launches genetic test for perimenopause

A new commercially available genetic test for perimenopausal women has been launched by femtech firm Willbe. 

The FemGene test is aimed at decoding “how women uniquely experience perimenopause and respond to bioidentical hormone therapy (BHRT)”.

Perimenopause, affecting over 1 billion women globally, remains one of the most underserved areas of healthcare, WIllbe says.

Standard approaches , the firm says, often rely on years of trial and error, leaving women and their doctors frustrated, unsupported, and at risk of preventable age-related conditions.

Willbe aims to predict how a woman’s body will metabolise and respond to declining hormones, long before symptoms take hold.

Its approach classifies women into distinct hormonal archetypes “rooted in genetics that guide treatment pathways with accuracy and confidence”.

This, it says, “enables faster relief, longer adherence to BHRT, and ultimately supports healthier, longer lives for women”.

The company was founded by entrepreneur Yulia Mintchin

She says: “Perimenopause is not just declining hormones — it’s an epigenetic reprogramming event.

“The body says: the way I used to run no longer works. Whether a woman thrives or struggles is written in her genes.

“As hormones decline, gene expression shifts — driving how she ages, repairs, and restores. That’s why women on the same HRT dose can have completely different outcomes.

“By decoding each woman’s genetic blueprint, we can predict her hormonal journey and deliver targeted solutions from day one.

“This is the moment women move beyond trial-and-error healthcare into precision longevity medicine.”